Dhrubajyoti Ghosh | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Dhrubajyoti Ghosh | Clinical Trials | Best Researcher Award

Postdoctoral Research Scholar at Duke University Hospital | United States

Dr. Dhrubajyoti Ghosh is a Postdoctoral Research Associate at the Department of Biostatistics and Bioinformatics, Duke University. His academic and research trajectory spans advanced statistical methodologies with strong applications in data science, biostatistics, longitudinal analysis, and time series modeling. Dr. Ghosh has contributed to diverse interdisciplinary projects, including Alzheimer’s disease, air quality, stock markets, and social media analytics. He has published in top-tier journals and collaborated on multiple funded projects, combining theory with real-world biomedical and environmental challenges. His work exemplifies a balanced integration of innovative statistical theory, computational tools, and impactful applied research.

Publication Profile 

Orcid

Education 

Dr. Ghosh earned his Ph.D. in Statistics from Washington University in St. Louis , where his thesis focused on time series analysis, uncertainty quantification, and applications in data science. He was advised by Professors Soumendra Lahiri and Tucker McElroy. Before that, he completed his M.Stat.  and B.Stat.  from the prestigious Indian Statistical Institute, Kolkata. His academic foundation has provided him with a rigorous grounding in statistical theory, methods, and real-world data analytics, enabling his impactful contributions in both academic and interdisciplinary research areas, including clinical trials and predictive modeling.

Experience 

Dr. Ghosh has served as a Postdoctoral Research Associate at Duke University, collaborating on biostatistical projects under Prof. Sheng Luo. , he held teaching assistant roles at Washington University in St. Louis and North Carolina State University. He also worked as a Research Assistant at the Laboratory for Analytic Sciences. His experience spans statistical software development, teaching undergraduate and graduate statistics, and collaborative research in longitudinal modeling, neurodegenerative diseases, and social media analysis, demonstrating a blend of strong theoretical foundation and practical implementation in applied statistics.

Awards and Honors 

Dr. Ghosh has received multiple recognitions throughout his academic career, including selection for student paper competitions at the International Indian Statistical Association (IISA) Conference. His work has been featured in renowned conferences such as JSM, IISA, LAS Symposium, and SDSS. He has contributed to prominent journals and served as a key collaborator in major interdisciplinary research projects, especially in medical imaging and neurodegenerative disease studies. His publications in high-impact journals, including Journal of Alzheimer’s Disease and Statistics in Biopharmaceutical Research, underline his growing reputation as an innovative and impactful researcher in modern statistical applications.

Research Focus 

Dr. Ghosh’s research focuses on advanced statistical methodologies, including time series analysis, non-parametric methods for longitudinal clinical trials, ensemble survival analysis, and predictive modeling using biomarkers. His contributions extend to social media analytics, air quality extremes, and causal inference in neuroscience. He has developed statistical tools for model validation, goodness-of-fit, and has proposed novel testing strategies for clinical applications. His interdisciplinary work involves statistical consulting in medical imaging, Alzheimer’s disease progression, and machine learning integration. His research addresses key methodological gaps in healthcare data science, striving for robust, interpretable, and scalable statistical solutions in public health.

Publication Top Notes

  • THANOS: A Predictive Model of Electoral Campaigns Using Twitter Data and Opinion Polls

  • A Non-Parametric U-Statistic Testing Approach for Multi-Arm Clinical Trials with Multivariate Longitudinal Data

  • Demographic Distribution Matching Between Real World and Virtual Phantom Population

  • XCAT 3.0: A Comprehensive Library of Personalized Digital Twins Derived from CT Scans

  • Penalized FCI for Causal Structure Learning in a Sparse DAG for Biomarker Discovery in Parkinson’s Disease

  • Polyspectral Mean Based Time Series Clustering of Indian Stock Market

Vibeke Strand | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology 🎓 and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 🧠📚. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 🏥💉. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 🔬🧪. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field 🧠👏. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact 🌟📘. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib 💊📊. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies 📝💼. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Hoda Salem | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Hoda Salem | Clinical Trials | Best Researcher Award

Prof. Dr. Hoda Salem, University of Tabuk, Saudi Arabia

Prof. Dr. Hoda Salem 🎓 is a distinguished clinical pharmacy expert with a Ph.D. in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. With over two decades of academic and clinical experience, she currently serves as Professor at Tabuk University, Saudi Arabia 🇸🇦. She has led numerous funded research projects, particularly in neuropharmacology and pharmacogenetics 🧬🧠. A prolific scholar, Dr. Salem has published in Q1 journals 📚 and actively mentors Ph.D. and MSc students. Her contributions extend to curriculum development, hospital training, and quality assurance in education 🌍. She’s a driving force in pharmacy education and clinical research excellence.

Publication Profile

Google Scholar

Education

Prof. Dr. Hoda Salem 🎓 earned her Bachelor’s degree in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. She continued her academic journey with a Master’s degree (M.Sc.) in Clinical Pharmacy from the same university, demonstrating early on her commitment to specialized healthcare and pharmaceutical practice 💊. Her pursuit of excellence culminated in a Ph.D. in Clinical Pharmacy in 2008 🧪, also from Tanta University. This strong academic foundation laid the groundwork for her impactful career in clinical pharmacy, education, and research, making her a respected figure in both Egyptian and international pharmaceutical education and clinical advancement.

Experience

Prof. Dr. Hoda Salem ⚕️ has made significant contributions to both scientific and clinical work in pharmacy education and healthcare. She played a pivotal role in quality assurance and accreditation by leading the self-study efforts and contributing to strategic planning at Tabuk and Al-Azhar Universities 📊📚. As a committee member, she helped supervise undergraduate examinations and mentored numerous Ph.D. and M.Sc. research projects 🎓🧬. Her clinical work includes patient counseling, drug dispensing, and providing accurate drug information to healthcare professionals at Tanta University Hospitals 💊🏥, reinforcing her commitment to enhancing both education and patient care.

Research Focus

Prof. Dr. Hoda Salem’s 🧪 research focus lies in clinical pharmacy, pharmaceutics, and neuropharmacology with a multidisciplinary approach integrating nanotechnology, drug delivery systems, and natural compounds. Her publications explore the treatment of diseases such as Alzheimer’s 🧠, Parkinson’s, ADHD, and fungal infections, along with oncology 🧬 and pharmacogenetics in breast cancer therapy. She has also worked on innovative therapies like solid lipid nanoparticles, niosomal gels, and bone marrow stem cell applications. Her clinical trials and lab studies reflect a deep commitment to therapeutic innovation, patient care, and translational research 💊🔬, bridging pharmaceutical science and clinical outcomes for better healthcare.

Publication Top Notes

Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study‏

Neuroprotective effects of phytochemicals against aluminum chloride-induced Alzheimer’s disease through ApoE4/LRP1, wnt3/β-catenin/gsk3β, and TLR4/NLRP3 pathways with physical …‏

Neuroprotective effect of morin hydrate against attention-deficit/hyperactivity disorder (ADHD) induced by MSG and/or protein malnutrition in rat pups: Effect on oxidative …‏

Autologous transplantation of CD34+ bone marrow derived mononuclear cells in management of non-reconstructable critical lower limb ischemia‏

A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major‏

The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy‏

Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients‏

Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major‏

Formulation, in-vitro and in-vivo evaluation of nystatin topical gel‏

DEVELOPMENT AND CLINICAL EVALUATION OF TOPICAL HYDROQUINONE NIOSOMAL GEL FORMULATION FOR THE TREATMENT OF MELASMA‏

Effect of oral Methyl Prednisolone on different radiological patterns of hypersensitivity pneumonitis‏

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Dvora Joseph Davey | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dvora Joseph Davey | Clinical Trials | Best Researcher Award 

Dr Dvora Joseph Davey, University of California, Los Angeles, UCLA, South Africa

Dr. Dvora Joseph Davey is a distinguished epidemiologist with a focus on infectious diseases, particularly HIV and STIs. Holding a Ph.D. in Epidemiology from UCLA, her research, mainly in sub-Saharan Africa, aims to reduce the burden of HIV through innovative interventions. As a Principal Investigator in clinical trials, Dr. Davey has contributed significantly to global HIV prevention efforts, especially for pregnant women. She is actively involved in policy-making with groups like the WHO and NIH, shaping global health initiatives. Her leadership, extensive research, and mentorship in global health make her an exemplary figure in public health. 🌍🔬💉

Publication Profile

google scholar

scopus

orcid

Education

Dr. Dvora Joseph Davey has an impressive academic background, beginning with a B.A. in International Affairs and French from the University of Colorado, Boulder, in 1998. She went on to earn a Master of Public Health (M.P.H.) in Population and Reproductive Health Sciences from Columbia University in 2003. Dr. Davey completed her Ph.D. in Epidemiology at the University of California, Los Angeles, in 2016, followed by a fellowship in Epidemiology of HIV at the University of North Carolina in 2017. She furthered her expertise with a postdoctoral fellowship in Global HIV Prevention at UCLA in 2018. 🌍📚

Scientific Appointments

Dr. Dvora Joseph Davey has held several prestigious positions throughout her career. Currently, she serves as an Associate Professor in Infectious Diseases and Epidemiology at UCLA’s School of Medicine and School of Public Health, respectively. She also holds honorary roles at the University of Cape Town and Desmond Tutu Health Foundation. Dr. Davey’s research includes being the Principal Investigator on a study about sexual behavior and PrEP acceptability. Her past positions include HIV Director at Population Services International in Mozambique and Director at the Rwanda-Emory HIV Research Group. With her diverse roles, Dr. Davey has had a significant global impact. 🌍🩺📊

Professional Memberships

Dr. Dvora Joseph Davey has made significant contributions to the field of HIV and reproductive health, serving as an Assistant Editor for renowned journals such as AIDS, JIAS, and PloS Global Health. She is also an active member of the South African Clinical Research Association and the American Public Health Association. Her honors include invitations to present at major conferences like HIVR4P 2024 in Peru and WHO Working Group meetings. Dr. Davey has co-chaired several influential research working groups, including on PrEP in pregnancy, and received multiple awards, including UCLA’s Epidemiology Department Summer Fellowship. 🌍📚🎤

Awards

Dr. Dvora Joseph Davey is a renowned researcher whose work focuses on HIV prevention and treatment, particularly in pregnant and breastfeeding women. Her studies address key challenges in high HIV incidence communities, especially in Sub-Saharan Africa. Dr. Davey investigates Pre-exposure Prophylaxis (PrEP) access, adherence, and effectiveness among pregnant women, emphasizing the need for female-controlled HIV prevention methods during vulnerable periods. Additionally, she explores the integration of STI testing, alcohol use, and the impact of intimate partner violence on HIV risk. Her contributions significantly influence HIV-related healthcare policies, aiming to reduce transmission and improve outcomes in these populations. 👩‍🔬🌍💉

Policy Involvement

Dr. Dvora Joseph Davey has made significant contributions to national and international HIV and STI policy-making. Her leadership in key working groups, including the National PrEP and Prevention of Vertical Transmission of HIV Working Groups, as well as the World Health Organization’s Working Group on Long-Acting PrEP in pregnancy, highlights her expertise and influence. These positions enable Dr. Davey to play a pivotal role in translating scientific research into actionable policies, ensuring her work impacts not only the scientific community but also global health policies. Her efforts amplify the reach of her research, making a lasting impact on public health worldwide. 🌍🩺💉

Leadership

Dr. Dvora Joseph Davey’s leadership in managing large-scale clinical trials and mentoring emerging public health and epidemiology professionals showcases her dedication to education and capacity-building in global public health. As a recipient of the prestigious NIH/Fogarty International Research Scientist Development Award (IRSDA) and the follow-on R01 award, Dr. Davey has solidified her position as a thought leader in the field. Her commitment to fostering continuous learning and improvement within the global health community reflects her deep influence and dedication to advancing public health practices worldwide. 🎓🌍💉👩‍🔬

Ongoing Projects

Dr. Dvora Joseph Davey’s ongoing research, supported by NIH and Gilead Corporation, plays a crucial role in addressing HIV within vulnerable populations. Her work on projects like PrEP-PP and SCOPE-PP, alongside innovative initiatives such as a community-based peer-led intervention to tackle alcohol use and HIV risk in pregnant women, highlights her proactive approach to solving complex public health challenges. Dr. Davey’s research aims to create effective, targeted solutions that address the unique needs of at-risk communities, contributing significantly to advancing HIV prevention and care efforts. 💡🧑‍🔬🩺🌍

Research Focus

Dr. Dvora Joseph Davey is a prominent researcher specializing in HIV prevention, sexually transmitted infections (STIs), and maternal health. Her work focuses on pre-exposure prophylaxis (PrEP) for HIV, examining its safety and efficacy among pregnant and postpartum women. She also explores STI diagnostics, point-of-care testing, and the prevalence of curable STIs in low- and middle-income countries. Her research seeks to improve access to health interventions, particularly for vulnerable populations like men who have sex with men and transgender women. Dr. Davey’s contributions help shape public health strategies for HIV prevention and sexual health. 🦠💉

Publication Top Notes